preview incl model chang acct
chang pipelin valu
expect solid partner sni report stronger-than-expect dupix
sale eylea sale may see impact expect dupi sale
continu grow eylea sale temporarili weaken amid pandem rebound
updat antibodi dev interim analysi libtayo piii trial could
serv major catalyst reiter buy rate new pt
eylea may near-term impact may start affect
eylea sale march pt defer visit use lucenti sale proxi q/q
lower estim eylea anoth reflect
impact eylea estim vs con furthermor
recent feedback virtual day suggest inject volum
due covid miss appt roughli increas sinc covid
kol say site live call patient vs robo call eas patient concern
dupix sale remain strong amid pandem sanofi report dupi revenu
ww us ex-u beat con ww us
ex-u repres growth q/q y/i strong perform
mainli driven underli demand amid jump vs
feb minim impact stock self-administr featur may facilit
dupi take share biolog requir administr hc profession
look add color management dupi growth trajectori comment
upcom readout eoe mid-year trial label expans
eye program combat develop novel antibodi cocktail
neutral assess kevzara inhibit sever patient
last updat management aim select two lead antibodi cocktail mid-
april start clinic test begin summer multipl trial evalu
kevzara sever patient underway collabor partner sni first trial
libtayo nsclc piii trial interim analysi could serv major catalyst
expect continu sale growth libtayo cscc look management provid
statu updat on-going oncolog trial major upcom catalyst libtayo includ
pivot readout interim readout nsclc later recal
libtayo demonstr orr vs w/ chemo first interim analysi
model updat updat model follow account present
chang praluent restructur reduc estimate eylea reflect
impact ad valuat dupi eoe peak sale
risk-adj light upcom readout also includ nsclc libatyo
bring peak sale model fl dlbcl peak sale
program matur togeth pt increas
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
expect us sale ex-u profit share
eylea
expect us sale ex-u royalti
praluent
expect ww profit share dupix
expect ww profit share kevzara
expect us profit share ex-u profit share
libtayo
stabl eylea share market entri anti-vegf
approv dupix follow-on indic includ
libtayo nsclc trial result better expect
faster regulatori path market anticip
declin eylea share market entri anti-vegf
medicar part reimburs eylea declin
follow implement model similar
program develop unsucess
includ wamd crvo dme eylea oppi
nasal polyp eoe dupix oppi
includ cscc nsclc libtayo oppi
includ fl dlbcl opp
bispecif antibodi program io combo
may pdufa date dupix atop
readout potenti pivot studi libtayo
readout portion /iii trial
dupix eoe
interim analysi os pivot studi
libtayo monotherapi nsclc
regulatori decis dupix atop
dermat adult china atop dermat
year eu
readout trial atop
readout piii trial dupix pediatr
readout trial dupix peanut allergi
updat
pleas see import disclosur inform page report
exhibit updat sale project product
arriv pt base dcf valuat model wacc tgr
share outstand estim million model includ sale estim eylea
eylea contribut major revenu follow dupix libtayo estim
eylea us revenu billion ex-u revenu billion includ
collabor revenu gener antibodi immuno-oncolog collabor
sanofi
commerci risk delay market entri chang reimburs and/or potenti
competit threat could lead us revis estim price target and/or rate
regulatori failur fda and/or ema may delay approv regeneron
investig target delay approv could lead chang estim price
clinic failur compani biotechnolog pharmaceut develop
treatment futur clinic failur on-going clinic trial may impact
competit risk exist treatment wet hypercholesterolemia
rheumatoid arthriti atop dermat asthma late-stag emerg therapi
near/mid-term downsid risk relat competit drug show better clinic profil
regeneron drug
pleas see import disclosur inform page report
